Search results for " Malignant"

showing 10 items of 91 documents

Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma

2020

Research for the most selective drug delivery to tumors represents a fascinating key target in science. Alongside the artificial delivery systems identified in the last decades (e.g., liposomes), a family of natural extracellular vesicles (EVs) has gained increasing focus for their potential use in delivering anticancer compounds. EVs are released by all cell types to mediate cell-to-cell communication both at the paracrine and the systemic levels, suggesting a role for them as an ideal nano-delivery system. Malignant pleural mesothelioma (MPM) stands out among currently untreatable tumors, also due to the difficulties in achieving an early diagnosis. Thus, early diagnosis and treatment of …

0301 basic medicineAntineoplastic AgentsReviewexosomesExtracellular vesiclesCatalysisInorganic Chemistrylcsh:Chemistry03 medical and health sciencesdrug delivery systems0302 clinical medicinemedicineHumansexosomedrug delivery systemmalignant pleural mesotheliomaMesotheliomaPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5SpectroscopyDrug Carriersbusiness.industryPleural mesotheliomaMesothelioma MalignantOrganic ChemistryGeneral Medicinemedicine.diseaseMicrovesiclesComputer Science Applications030104 developmental biologylcsh:Biology (General)lcsh:QD1-999030220 oncology & carcinogenesisDrug deliveryCancer researchDelivery systemextracellular vesiclebusinessextracellular vesicles
researchProduct

[1,2]Oxazolo[5,4-e]isoindoles as promising tubulin polymerization inhibitors

2016

Abstract A series of [1,2]Oxazolo [5,4- e ]isoindoles has been synthesized through a versatile and high yielding sequence. All the new structures showed in the 1 HNMR spectra, the typical signal in the 8.34–8.47 ppm attributable to the H-3 of the [1,2]oxazole moiety. Among all derivatives, methoxy benzyl substituents at positions 3 and 4 or/and 5 were very effective in reducing the growth of different tumor cell lines, including diffuse malignant peritoneal mesothelioma (DMPM), an uncommon and rapidly malignancy poorly responsive to available therapeutic options. The most active compound 6j was found to impair tubulin polymerization, cause cell cycle arrest at G2/M phase and induce apoptosi…

0301 basic medicineCell cycle checkpointIsoindoles2]Oxazolo[5StereochemistryDiffuse malignant peritoneal mesotheliomaα-hydroxyalkyl ketonesAntineoplastic AgentsApoptosisIsoindoles01 natural sciencesTubulin Polymerization Inhibitors03 medical and health scienceschemistry.chemical_compoundIsomerismTubulinCell Line TumorDrug DiscoveryHumansMoietyProtein Structure QuaternaryOxazole[12]Oxazolo[54-e]isoindolePharmacology010405 organic chemistryChemistryAntitubulin agentsDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaTubulin Modulators0104 chemical sciencesAntitubulin agentG2 Phase Cell Cycle Checkpointsα-hydroxyalkyl ketone030104 developmental biologyApoptosisActive compound4-e]isoindolesProton NMRM Phase Cell Cycle CheckpointsAntitubulin agents; Diffuse malignant peritoneal mesothelioma; [1; 2]Oxazolo[5; 4-e]isoindoles; α-hydroxyalkyl ketones; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry[1Drug Screening Assays AntitumorProtein Multimerization
researchProduct

Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.

2018

0301 basic medicineMesotheliomaLung NeoplasmsPleural NeoplasmsPemetrexed03 medical and health sciences0302 clinical medicineGeneticsmedicineBiomarkers TumorHumansMesotheliomaProton-coupled folate transporterPharmacologybusiness.industryPleural mesotheliomaMesothelioma Malignantmedicine.diseasechemoresistance mesothelioma PCFT pemetrexed030104 developmental biologyPemetrexedDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchMolecular MedicineBiomarker (medicine)businessProton-Coupled Folate Transportermedicine.drugPharmacogenomics
researchProduct

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

2020

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a signifi…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentClinical BiochemistryKaplan-Meier EstimateDisease-Free SurvivalDrug Administration ScheduleNO03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungDrug DiscoverymedicineMalignant pleural effusionHumansimmunotherapy; malignant pleural effusion; nivolumab; non-small-cell lung cancerIn patientmalignant pleural effusionLung cancerImmune Checkpoint InhibitorsRetrospective StudiesPharmacologynivolumabbusiness.industryBrain NeoplasmsLiver NeoplasmsImmunotherapymedicine.diseasePrognosisPleural Effusion Malignantrespiratory tract diseases030104 developmental biologyTreatment Outcomenon-small-cell lung cancer030220 oncology & carcinogenesisFemalesense organsNon small cellimmunotherapyNivolumabbusiness
researchProduct

The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

2016

Abstract: Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleura with a poor prognosis. The most active first-line regimens are platinum compounds and pemetrexed. There is no standard second-line treatment in MPM. Advances in the understanding of tumor molecular biology have led to the development of several targeted treatments, which have been evaluated in clinical trials. Unfortunately none of the explored targeted treatments can currently be recommended as routine treatment in MPM. We reviewed the biological pathways involved in MPM, the clinical trials about targeted therapy, and possible related mechanisms of resistance. We suggest that specific genetic markers are n…

0301 basic medicineOncologyDrugMesotheliomamedicine.medical_specialtyPathologyLung NeoplasmsSettore MED/06 - Oncologia Medicamedia_common.quotation_subjectmedicine.medical_treatmentPleural NeoplasmsResistanceAntineoplastic AgentsTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsHumansMesotheliomaMolecular Targeted Therapymedia_commonPleural mesotheliomabusiness.industryPlatinum compoundsMesothelioma MalignantHematologymedicine.diseaseClinical trial030104 developmental biologyPemetrexedOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMutationPleuraMesothelioma; Pleura; Resistance; Targeted therapyMolecular ProfileHuman medicinebusinessmedicine.drug
researchProduct

Hypermineralocorticoidism and hypertension

1971

Die mit Hypokaliamie, Uberproduktion von Mineralocorticoiden (Aldosteron und/oder Corticosteron und Desoxycorticosteron) und Aktivitatsanderungen des Renin-Angiotensinsystems einhergehenden Hochdrucksformen werden beschrieben. Sie lassen sich nach willkurlich gewahlten biochemischen Kriterien in drei Gruppen einteilen: a) Hypermineralocorticoidismus mit Reninsuppression und Aldosteronismus, b) Hypermineralocorticoidismus mit Reninund Aldosteronsuppression und c) Hypermineralocorticoidismus mit erhohtem Plasmarenin und Aldosteronismus. Jede dieser Gruppen besteht aus mehreren Syndromen, die sich durch ihr adrenocorticales Sekretionsmuster und/oder ihre morphologischen Nebennierenrindenverand…

AdenomaGynecologymedicine.medical_specialtyAdrenocortical HyperfunctionHyperplasiabusiness.industryAdrenal Gland NeoplasmsHypokalemiaGeneral MedicineRenal Artery ObstructionDexamethasoneDiagnosis DifferentialHypertension MalignantMineralocorticoidsHyperaldosteronismHypertensionReninDrug DiscoverymedicineHumansMolecular MedicinebusinessAldosteroneCushing SyndromeGenetics (clinical)Klinische Wochenschrift
researchProduct

Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis.

2006

The recurrence of pleural effusions is a common event in a variety of neoplastic diseases. The objective of this study was to identify the mechanisms promoting the homing and growth of cancer cells within the pleural space. A cancer cell line recovered from malignant pleural fluids (lung adenocarcinoma cell line) that constitutively expresses cyclooxygenase 2 (COX-2) and all types of prostaglandin receptors was studied. It was first demonstrated using a matrigel system, that malignant pleural fluids increase the invasiveness of adenocarcinoma cells more than congestive heart failure (CHF) pleural fluids. Moreover, exposure to exudative malignant, but not to CHF pleural fluids, increased the…

AdultCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsPleural effusionAdenocarcinomaDinoprostoneMetastasisCell Line TumormedicineHumansReceptors Prostaglandin ENeoplasm InvasivenessProstaglandin E2PleurisyAgedCell ProliferationMatrigelCyclooxygenase 2 Inhibitorsbusiness.industryNF-kappa BCancerMiddle Agedmedicine.diseaseNeoplasm ProteinsPleural Effusion MalignantUp-RegulationOncologyPleurisyCyclooxygenase 2TalcCancer cellAdenocarcinomabusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Ventricular tachycardia in non-compaction of left ventricle: Is this a frequent complication?

2007

Background: Isolated left ventricular non-compaction is the result of incomplete myocardial morphogenesis, leading to persistence of the embryonic myocardium. The condition is recognized by an excessively prominent trabecular meshwork and deep intertrabecular recesses of the left ventricle. Whether these intertrabecular recesses are a favorable substrate for ventricular arrhythmias is unclear. Some reports have found that the fatal ventricular arrhythmias may occur in approximately half of the patients. In this report we investigated about this association. Methods and Results: In total we evaluated a continuous series of 238 patients affected by non-compaction. Periodic Holter monitoring w…

AdultHeart Defects CongenitalMalemedicine.medical_specialtyVentricular tachycardiaElectrocardiographyVentricular arrhythmiasIsolated left ventricular non-compaction; Malignant; Ventricular arrhythmias; Ventricular tachycardiaRisk FactorsInternal medicinemedicineHumansRegistriesisolated left ventricular non-compaction ventricular arrhythmias ventricular tachycardia malignantcardiovascular diseasesRisk factorRetrospective StudiesMALIGNANCYIsolated left ventricular non-compactionMalignantbusiness.industryVentricular tachycardiaGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureItalyVentricleAnesthesiaChild PreschoolVentricular fibrillationCardiologyTachycardia Ventricularcardiovascular systemFemaleTrabecular meshworkCardiology and Cardiovascular MedicinebusinessComplicationHolter monitoringVENTRICULAR ARRHYTHMIAS.
researchProduct

Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer:The PanCareS…

2022

Late mortality of European five-year survivors of childhood or adolescent cancer has dropped over the last 60 years, but excess mortality persists. There is little information concerning secular trends in cause-specific mortality among older European survivors. PanCareSurFup pooled data from 12 cancer registries and clinics in 11 European countries from 77 423 five-year survivors of cancer diagnosed before age 21 between 1940 to 2008 followed for an average age of 21 years and a total of 1.27 million person-years to determine their risk of death using cumulative mortality, standardized mortality ratios (SMR), absolute excess risks (AER), and multivariable proportional hazards regression ana…

AdultMaleCancer ResearchSecond NeoplasmsAdolescentAdolescent cancercauses of deathEuropean03 medical and health sciencesYoung Adult0302 clinical medicineCancer SurvivorsCause of DeathMedicineHumans030212 general & internal medicineCause specificChild610 Medicine & healthAgedExcess mortalitybusiness.industrycardiovascularsecond malignant neoplasmsHazard ratioCancersurvivors of childhood cancerMiddle Agedmedicine.diseaseConfidence interval3. Good healthOncologyEuropean; cardiovascular; causes of death; late mortality; second malignant neoplasms; survivors of childhood cancer030220 oncology & carcinogenesisChild Preschoollate mortalityFemaleRisk of deathbusiness360 Social problems & social servicesDemography
researchProduct

Mid-term trends and recent birth-cohort-dependent changes in incidence rates of cutaneous malignant melanoma in Italy

2020

In Oceania, North America and north-western Europe, after decades of increase, cutaneous malignant melanoma (CMM) rates began to stabilise or decline before 2000. Anecdotal evidence suggests that the reversal of the incidence trend is extending to southern Europe. To obtain a formal confirmation, this nationwide study from Italy investigated the incidence trends by birth cohort. Twenty-one local cancer registries covering a population of 15 814 455 provided incidence data for primary CMM registered between 1994 and 2013. Trends in age-standardised rates were analysed using joinpoint regression models and age-period-cohort models. Age-standardised incidence showed a consistent increase throu…

AdultMaleCancer ResearchSkin NeoplasmsAdolescentAge-period-cohort modelling birth cohort cutaneous malignant melanoma incidence time trendPopulationSocio-culturaleRate ratioSettore MED/42 - Igiene Generale E ApplicataRisk AssessmentYoung Adult03 medical and health sciences0302 clinical medicineage-period-cohort modellingHumansMedicineRegistrieseducationMelanomaAgedAged 80 and overeducation.field_of_studyGeographybusiness.industryIncidence (epidemiology)Melanomabirth cohortMiddle Agedmedicine.diseaseConfidence intervalAnnual Percent Changetime trendItalyOncology030220 oncology & carcinogenesisCohortincidenceFemalebusinessBirth cohortcutaneous malignant melanomaDemography
researchProduct